Avalanche Biotechnologies to Present at Upcoming Scientific Meetings
ARVO 2016 Annual Meeting
Presentation Session #266
Intraocular Gene Expression and Functional Safety Evaluation Following Intravitreal Delivery of Cone Specific GFP-Expressing AAV Vectors in Nonhuman Primates
Presenter:
Poster Session # 141
Presentation # 781
Temporal Expression of Cone-Specific Recombinant Adeno-Associated Viruses in Multiple Species Exhibiting Various Cone Levels as Potential Models to Treat Cone-Associated Disorders
Presenter:
Presentation # 782
In Vivo Assessment of the Impact of Neutralizing Antibodies on Intravitreal AAV2.7m8 Administration
Presenter: Annahita Keravala, PhD,
Presentation # 786
Evaluation of AAV Variants for Transgene Expression and Distribution in Rabbit and Non-Human Primate Eyes Following Intravitreal Delivery
Presenter:
Poster Session # 324
Presentation # 3369
Anatomical and Functional Effects of Subretinal rAAV.sVEGFR-1 Gene Therapy on Retinal Choroidal Structures in Nonhuman Primates
Presenter: Kathryn Woodburn PhD,
ASGCT 2016 Annual Meeting
Session title: Delivery Questions for Neural Applications
Room: Exhibit Hall C & B South
Abstract # 607
Organotypic Culture of Adult Porcine Retina as an In Vitro Screening Model for AAV-Mediated Gene Therapy in Ophthalmology
Presenter: Annahita Keravala, PhD,
About Avalanche Biotechnologies, Inc.
Avalanche is a gene therapy company committed to discovering and developing novel medicines that can offer potentially life-changing therapeutic benefit to patients suffering from diseases with few or burdensome treatment options. Avalanche is leveraging its next generation adeno-associated virus (AAV)-based directed evolution platform to generate product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. With significant capabilities and expertise in vector optimization, process development and manufacturing, Avalanche seeks to discover and develop targets in ophthalmology and beyond. For more information, please visit www.avalanchebiotech.com.
CONTACT: Investor ContactLauren Glaser (650) 656-9347 lauren@avalanchebiotech.com